Response High for Bispecific Antibody Talquetamab in Multiple Myeloma

Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

IMscin001 Part 2: A Randomised Phase 3, Open-label, Multicentre Study Examining the Pharmacokinetics, Efficacy, Immunogenicity, and Safety of Atezolizumab Subcutaneous versus Intravenous in Previously Treated Locally Advanced or Metastatic NSCLC

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

Response High for Bispecific Antibody Talquetamab in Multiple Myeloma

header-info

Mar, 21, 2023

A substantial proportion of patients with heavily pretreated multiple myeloma responded to treatment with the bispecific antibody talquetamab, according to results of a phase I study published in The New England Journal of Medicine. Dr. Chari and colleagues noted that the overall results of this study are limited by the early and ongoing status of the study, which included only a small number of patients at each dose, and its single-group design.

Access the full article to read more here.